



Utah Department of
Health & Human Services

UTAH DEPARTMENT OF HEALTH & HUMAN SERVICES AGREEMENT AMENDMENT

25169934

Department Log Number

252700934

State Agreement ID

1. **AGREEMENT NAME:** The name of this agreement is Disease Response, Evaluation, Analysis and Monitoring 2024 - San Juan County Health Department - Amendment 1.
2. **PARTIES:** This amendment is between the Utah Department of Health & Human Services (“**DHHS**”) and San Juan County.

PAYMENT ADDRESS

San Juan County
735 S 200 W, Ste 2
Blanding, UT 84511

MAILING ADDRESS

San Juan County
735 S 200 W, Ste 2
Blanding, UT 84511

3. **PURPOSE OF AMENDMENT:** The purpose of this amendment is to increase the contract amount and replace Attachment A in exchange for continued services.
4. **CHANGES TO AGREEMENT:**
 1. The contract amount is being changed. The original amount was \$12,179.00. The funding amount will be increased by \$8,699.00 in federal funds. The new total funding is \$20,878.00.
 2. Attachment A: Scope of Work (attached) is replacing Attachment A: Utah Department of Health and Human Services Subrecipient Terms. The General Provisions are no longer required as an attachment to this agreement, as per agreement 251691202 General Provisions and Business Associate Agreement. Attachment B is deleted. The document title is changed. Article 1 Purpose, Section 1.1 Purpose is changed. Article 3 Cross-Cutting Epidemiology/Outbreak Capacity, Section 3.1(3) is changed. Article 4 Funding, Section 4.1(1)(B), (1)(C), and (2)(B) are added.

UEI: WCVABP2FEVA2

All other conditions and terms in the original agreement and previous amendments remain the same.

5. **EFFECTIVE DATE OF AMENDMENT:** This amendment is effective 08/01/2025.

Intentionally Left Blank

Contract with Utah Department of Health & Human Services and San Juan County , Log # 25169934

IN WITNESS WHEREOF, the parties enter into this agreement.

Signature

Signed by: _____

Lori Maughan
Commission Chair

Date Signed: _____

Attachment A: Scope of Work
Disease Response, Evaluation, Analysis, and Monitoring 2024 - San Juan County Health Department
Amendment 1

Article 1
PURPOSE

- 1.1 **Purpose.** The purpose of this grant is to provide cross-cutting epidemiology/outbreak response and capacity for infectious diseases, such as vaccine-preventable diseases and mycotics. Funds may not be used to investigate tuberculosis (“**TB**”) or sexually transmitted infections (“**STI**”) as this is not within scope of ELC funding.

Article 2
DEFINITIONS

- 2.1 **Definitions.** In this grant, the following definitions apply:

“**EpiTrax**” means the State of Utah disease reporting system.

Article 3
GRANTEE RESPONSIBILITIES

- 3.1 **Cross-Cutting Epidemiology/Outbreak Capacity.** The Grantee shall:

- (1) comply with Disease Plans/Case Report Forms and Disease Reporting (<https://epi.utah.gov/plans-and-reports-atozlist/>) and Centers for Disease Control and Prevention guidance for conditions found at (https://epi.utah.gov/wp-content/uploads/Rpt_Disease_List.pdf);
- (2) enter investigation findings in EpiTrax;
- (3) maintain sufficient epidemiology staff to investigate and respond to outbreaks within the Grantee’s jurisdiction, contingent on appropriate funding. If the grantee does not have sufficient epidemiology capacity to manage the requirements of this agreement, Local Health Officer (“**LHO**”) shall bring the epidemiology capacity issue to Epidemiology and Informatics Executive Group (“**EIE**”) for review and support the EIE decision; and
- (4) have the option of completing the following activities:
 - (A) detect, investigate, and respond to outbreaks;
 - (B) assist DHHS in obtaining information on products that may be the source of an outbreak; and
 - (C) collect and ship outbreak specimens to Utah Public Health Lab (“**UPHL**”).

3.2 **Vaccine Preventable Disease.** The Grantee shall:

- (1) investigate reportable vaccine-preventable disease cases and outbreaks including; varicella, diphtheria, measles, mumps, rubella, Neisseria meningitidis, Haemophilus influenzae, pertussis, S. pneumoniae, tetanus, and acute flaccid myelitis ("**AFM**");
- (2) collect and enter case data, key and enhanced variable data into EpiTrax;
- (3) work with DHHS to ensure that all Neisseria meningitidis isolates from normally sterile sites are sent to UPHL for serogroup/serotype confirmation testing;
- (4) work with DHHS to ensure that all Haemophilus influenzae isolates from normally sterile sites are sent to UPHL for serogroup/serotype confirmation testing;
- (5) work with DHHS to ensure that all diphtheria isolates from normally sterile sites are sent to UPHL for confirmation and toxin screening;
- (6) work with DHHS to investigate and complete enhanced variables for severe or hospitalized cases of varicella;
- (7) collaborate with DHHS to improve the completeness of vaccine preventable disease data such as hospitalization, mortality status, vaccination status, and clinical information; and
- (8) investigate suspect cases of AFM by communicating with medical providers, laboratories and other partners, reviewing clinical information and submitting investigation forms to DHHS;
 - (A) Case investigation may be deferred to DHHS.
 - (B) For AFM cases, the Grantee may:
 - (i) work with DHHS to ensure that all AFM specimens are sent to UPHL;
 - (ii) conduct a 60-day post limb weakness onset follow up on confirmed and probable cases of AFM cases using a standardized questionnaire; and/or
 - (iii) defer follow-up to DHHS.

Article 4
FUNDING

4.1 **Funding.**

- (1) For Cross-Cutting Epidemiology/Outbreak Capacity:
 - (A) \$8,699.00 for the period November 15, 2024 to July 31, 2025.

(B) \$8,699.00 for the period August 1, 2025 to July 31, 2026.

(C) \$7,122.40 unspent funds from the previous period may be spent during the period August 1, 2025 to July 31, 2026.

(2) For Vaccine Preventable Disease:

(A) \$3,480.00 for the period November 15, 2024 to July 31, 2025.

(B) \$3,025.98 unspent funds from the previous period may be spent during the period August 1, 2025 to July 31, 2026.

Article 5 INVOICING

5.1 **Invoicing.** The Grantee shall include one column for each funding source in the Monthly Expenditure Report, including:

(1) Cross-cutting Epi/Outbreak Response; and

(2) Vaccine Preventable Disease.

Article 6 OUTCOMES

6.1 **Outcomes.** The desired outcome of this grant is to manage the spread of reportable diseases in Utah.

6.2 **Performance Measure.** The number of disease investigations conducted for reportable infectious diseases.

6.3 **Reporting.** Monthly EpiTrax case count reporting.